
Saul N Faust

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8813619/publications.pdf Version: 2024-02-01



SALLI Ν ΕΛΙΙST

#	Article	IF	CITATIONS
1	Comparison of UK paediatric SARS-CoV-2 admissions across the first and second pandemic waves. Pediatric Research, 2023, 93, 207-216.	2.3	10
2	Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Children in Summer Schools Applying Stringent Control Measures in Barcelona, Spain. Clinical Infectious Diseases, 2022, 74, 66-73.	5.8	26
3	Biomarker-guided duration of Antibiotic Treatment in Children Hospitalised with confirmed or suspected bacterial infection (BATCH): protocol for a randomised controlled trial. BMJ Open, 2022, 12, e047490.	1.9	6
4	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet, The, 2022, 399, 36-49.	13.7	161
5	Multi-Excitation Raman Spectroscopy for Label-Free, Strain-Level Characterization of Bacterial Pathogens in Artificial Sputum Media. Analytical Chemistry, 2022, 94, 669-677.	6.5	13
6	Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. EClinicalMedicine, 2022, 44, 101262.	7.1	87
7	Antibiotics for lower respiratory tract infection in children presenting in primary care (ARTIC-PC): the predictive value of molecular testing. Clinical Microbiology and Infection, 2022, 28, 1238-1244.	6.0	3
8	Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Nature Cancer, 2022, 3, 552-564.	13.2	51
9	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial Journal of Infection, 2022, 84, 795-813.	3.3	43
10	Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infectious Diseases, The, 2022, 22, 1131-1141.	9.1	99
11	Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults. Journal of Infection, 2022, 85, 306-317.	3.3	12
12	Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. Clinical Microbiology and Infection, 2022, 28, 1649.e1-1649.e8.	6.0	20
13	Non-alcoholic fatty liver disease and childhood obesity. Archives of Disease in Childhood, 2021, 106, 3-8.	1.9	57
14	Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2021, 384, 693-704.	27.0	8,063
15	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	13.7	3,887
16	A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. The Lancet Child and Adolescent Health, 2021, 5, 133-141.	5.6	228
17	Research Evaluation Alongside Clinical Treatment in COVID-19 (REACT COVID-19): an observational and biobanking study. BMJ Open, 2021, 11, e043012.	1.9	12
18	COVID-19 symptom surveillance in immunocompromised children and young people in the UK: a prospective observational cohort study. BMJ Open, 2021, 11, e044899.	1.9	12

#	Article	IF	CITATIONS
19	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	13.7	979
20	Paediatric research in the times of COVID-19. Pediatric Research, 2021, 90, 267-271.	2.3	8
21	Mycotic aneurysm presenting as hip pain and severe anaemia. Archives of Disease in Childhood, 2021, 106, archdischild-2021-321632.	1.9	0
22	P051 Symptoms of COVID-19 and anxiety levels in adult patients receiving b-and ts-DMARDS using an online reporting system. Rheumatology, 2021, 60, .	1.9	0
23	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362.	13.7	540
24	Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. Med, 2021, 2, 701-719.e19.	4.4	73
25	Lupus, vaccinations and COVID-19: What we know now. Lupus, 2021, 30, 1541-1552.	1.6	21
26	A recombinant commensal bacteria elicits heterologous antigen-specific immune responses during pharyngeal carriage. Science Translational Medicine, 2021, 13, .	12.4	7
27	Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. Frontiers in Immunology, 2021, 12, 694759.	4.8	22
28	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	7.4	498
29	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet, The, 2021, 398, 856-869.	13.7	430
30	Antibiotics for lower respiratory tract infection in children presenting in primary care in England (ARTIC PC): a double-blind, randomised, placebo-controlled trial. Lancet, The, 2021, 398, 1417-1426.	13.7	32
31	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T _H 1 response with a diverse TCR repertoire. Science Translational Medicine, 2021, 13, eabj7211.	12.4	80
32	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, The, 2021, 398, 981-990.	13.7	214
33	RSV: perspectives to strengthen the need for protection in all infants. Emerging Themes in Epidemiology, 2021, 18, 15.	2.7	16
34	Powered Respirators Are Effective, Sustainable, and Cost-Effective Personal Protective Equipment for SARS-CoV-2. Frontiers in Medical Technology, 2021, 3, 729658.	2.5	3
35	Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine. JAMA Network Open, 2021, 4, e2128652.	5.9	29
36	The Effect of Haematocrit on Measurement of the Mid-Infrared Refractive Index of Plasma in Whole Blood. Biosensors, 2021, 11, 417.	4.7	3

#	Article	IF	CITATIONS
37	Incidental findings in UK healthy volunteers screened for a COVIDâ€19 vaccine trial. Clinical and Translational Science, 2021, , .	3.1	1
38	Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia. JAMA - Journal of the American Medical Association, 2021, 326, 1713.	7.4	57
39	Amoxicillin duration and dose for community-acquired pneumonia in children: the CAP-IT factorial non-inferiority RCT. Health Technology Assessment, 2021, 25, 1-72.	2.8	6
40	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet, The, 2021, 398, 2258-2276.	13.7	519
41	Controlled Human Infection With Bordetella pertussis Induces Asymptomatic, Immunizing Colonization. Clinical Infectious Diseases, 2020, 71, 403-411.	5.8	40
42	Mutations in <i>RPSA</i> and <i>NKX2â€3</i> link development of the spleen and intestinal vasculature. Human Mutation, 2020, 41, 196-202.	2.5	9
43	Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2020, 75, 117-125.	3.0	35
44	Thirteen-Valent Pneumococcal Conjugate Vaccine in Children With Acute Lymphoblastic Leukemia: Protective Immunity Can Be Achieved on Completion of Treatment. Clinical Infectious Diseases, 2020, 71, 1271-1280.	5.8	7
45	Inflammatory phenotyping predicts clinical outcome in COVID-19. Respiratory Research, 2020, 21, 245.	3.6	72
46	Problem-solving in clinical practice: Persisting respiratory distress in a premature infant. Archives of Disease in Childhood: Education and Practice Edition, 2020, 106, edpract-2019-317757.	0.5	0
47	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2020, 383, 2030-2040.	27.0	1,013
48	Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2020, 396, 1345-1352.	13.7	569
49	Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant series. Vaccine, 2020, 38, 5718-5725.	3.8	2
50	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478.	13.7	2,080
51	Immune reconstitution in children following chemotherapy for acute leukemia. EJHaem, 2020, 1, 142-151.	1.0	12
52	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	13.7	1,196
53	â€~Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents. BMJ Open, 2020, 10, e037358.	1.9	11
54	COVID-19 in children: current evidence and key questions. Current Opinion in Infectious Diseases, 2020, 33, 540-547.	3.1	49

#	Article	IF	CITATIONS
55	Children are not COVID-19 super spreaders: time to go back to school. Archives of Disease in Childhood, 2020, 105, 618-619.	1.9	169
56	High frequency of paediatric facial nerve palsy due to Lyme disease in a geographically endemic region. International Journal of Pediatric Otorhinolaryngology, 2020, 132, 109905.	1.0	5
57	Experts' opinion for improving global adolescent vaccination rates: a call to action. European Journal of Pediatrics, 2020, 179, 547-553.	2.7	12
58	Discovery of Cephalosporin-3′-Diazeniumdiolates That Show Dual Antibacterial and Antibiofilm Effects against <i>Pseudomonas aeruginosa</i> Clinical Cystic Fibrosis Isolates and Efficacy in a Murine Respiratory Infection Model. ACS Infectious Diseases, 2020, 6, 1460-1479.	3.8	18
59	Congenital syphilis presenting with liver lesions. International Journal of STD and AIDS, 2019, 30, 82-85.	1.1	2
60	Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia: a protocol for a randomIsed controlled Trial (CAP-IT). BMJ Open, 2019, 9, e029875.	1.9	10
61	Protocol for a controlled human infection with genetically modified <i>Neisseria lactamica</i> expressing the meningococcal vaccine antigen NadA: a potent new technique for experimental medicine. BMJ Open, 2019, 9, e026544.	1.9	6
62	Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study. BMC Pediatrics, 2019, 19, 50.	1.7	3
63	Diagnosis and treatment of biofilm infections in children. Current Opinion in Infectious Diseases, 2019, 32, 505-509.	3.1	2
64	Clinical Presentation of Influenza in Children 6 to 35 Months of Age. Pediatric Infectious Disease Journal, 2019, 38, 866-872.	2.0	17
65	Microbial epidemiology and carriage studies for the evaluation of vaccines. Journal of Medical Microbiology, 2019, 68, 1408-1418.	1.8	4
66	Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. Scientific Reports, 2018, 8, 3390.	3.3	34
67	Lyme disease: summary of NICE guidance. BMJ: British Medical Journal, 2018, 361, k1261.	2.3	19
68	Anticytokine autoantibodies in a patient with a heterozygous NFKB2 mutation. Journal of Allergy and Clinical Immunology, 2018, 141, 1479-1482.e6.	2.9	24
69	Antenatal vaccination against Group B streptococcus: attitudes of pregnant women and healthcare professionals in the <scp>UK</scp> towards participation in clinical trials and routine implementation. Acta Obstetricia Et Gynecologica Scandinavica, 2018, 97, 330-340.	2.8	13
70	Prevention of vaccine-matched and mismatched influenza in children aged 6–35 months: a multinational randomised trial across five influenza seasons. The Lancet Child and Adolescent Health, 2018, 2, 338-349.	5.6	51
71	A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. Vaccine. 2018. 36. 2300-2306.	3.8	12
72	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. Npj Vaccines, 2018, 3, 49.	6.0	51

#	Article	IF	CITATIONS
73	Life-threatening infections in children in Europe (the EUCLIDS Project): a prospective cohort study. The Lancet Child and Adolescent Health, 2018, 2, 404-414.	5.6	69
74	Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function. Pediatrics, 2018, 142, .	2.1	17
75	Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. Frontiers in Immunology, 2018, 9, 543.	4.8	137
76	Ecology and diversity in upper respiratory tract microbial population structures from a cross-sectional community swabbing study. Journal of Medical Microbiology, 2018, 67, 1096-1108.	1.8	5
77	Pneumococcal vaccine impacts on the population genomics of non-typeable Haemophilus influenzae. Microbial Genomics, 2018, 4, .	2.0	12
78	Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT. , 2018, , 18-32.		0
79	Cephalosporin-3′-Diazeniumdiolate NO Donor Prodrug PYRRO-C3D Enhances Azithromycin Susceptibility of Nontypeable Haemophilus influenzae Biofilms. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	26
80	Cephalosporin-NO-donor prodrug PYRRO-C3D shows β-lactam - mediated activity against Streptococcus pneumoniae biofilms. Nitric Oxide - Biology and Chemistry, 2017, 65, 43-49.	2.7	21
81	The rise and fall of pneumococcal serotypes carried in the PCV era. Vaccine, 2017, 35, 1293-1298.	3.8	68
82	Corticosteroids and infliximab impair the performance of interferon-Î ³ release assays used for diagnosis of latent tuberculosis. Thorax, 2017, 72, 946-949.	5.6	43
83	Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis. FEMS Microbiology Letters, 2017, 364, .	1.8	85
84	Investigating <i>Bordetella pertussis</i> colonisation and immunity: protocol for an inpatient controlled human infection model. BMJ Open, 2017, 7, e018594.	1.9	26
85	Bone and Joint Infections. Pediatric Infectious Disease Journal, 2017, 36, 788-799.	2.0	165
86	Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis. Molecular Therapy, 2017, 25, 2104-2116.	8.2	149
87	Primary ciliary dyskinesia ciliated airwayÂcells show increased susceptibility to <i>Haemophilus influenzae</i> biofilm formation. European Respiratory Journal, 2017, 50, 1700612.	6.7	31
88	Autoimmunity/inflammation in a monogenic primary immunodeficiency cohort. Clinical and Translational Immunology, 2017, 6, e155.	3.8	27
89	Pneumococcal conjugate vaccine implementation in middle-income countries. Pneumonia (Nathan Qld) Tj ETQ	41 1.0.784 6.1	∙314 rgBT /Ov 28
90	Clinical spectrum and features of activated phosphoinositide 3-kinase l̃´syndrome: AÂlarge patient cohort study. Journal of Allergy and Clinical Immunology, 2017, 139, 597-606.e4.	2.9	377

#	Article	IF	CITATIONS
91	Pre-vaccine serotype composition within a lineage signposts its serotype replacement – a carriage study over 7 years following pneumococcal conjugate vaccine use in the UK. Microbial Genomics, 2017, 3, e000119.	2.0	26
92	D-methionine interferes with non-typeable Haemophilus influenzae peptidoglycan synthesis during growth and biofilm formation. Microbiology (United Kingdom), 2017, 163, 1093-1104.	1.8	10
93	Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight, 2017, 2, .	5.0	109
94	Duration of intravenous antibiotic therapy for children with acute osteomyelitis or septic arthritis: a feasibility study. Health Technology Assessment, 2017, 21, 1-164.	2.8	19
95	Authors' reply to Eisenhut. BMJ, The, 2016, 355, i5787.	6.0	0
96	Mucosal-Associated Invariant T (MAIT) Cells Are Impaired in Th17 Associated Primary and Secondary Immunodeficiencies. PLoS ONE, 2016, 11, e0155059.	2.5	4
97	Natural resistance to Meningococcal Disease related to CFH loci: Meta-analysis of genome-wide association studies. Scientific Reports, 2016, 6, 35842.	3.3	33
98	Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy. Vaccine, 2016, 34, 6350-6357.	3.8	0
99	Parallel Evolution inStreptococcus pneumoniaeBiofilms. Genome Biology and Evolution, 2016, 8, 1316-1326.	2.5	8
100	<i>Pseudomonas aeruginosa</i> infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches. Expert Review of Respiratory Medicine, 2016, 10, 685-697.	2.5	114
101	Precision Molecular Diagnosis Defines Specific Therapy in Combined Immunodeficiency with Megaloblastic Anemia Secondary to MTHFD1 Deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 1160-1166.e10.	3.8	25
102	Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT. Pediatrics, 2016, 138, .	2.1	22
103	Suspected sepsis: summary of NICE guidance. BMJ, The, 2016, 354, i4030.	6.0	19
104	Precision treatment with sirolimus in a case of activated phosphoinositide 3-kinase δ syndrome. Clinical Immunology, 2016, 171, 38-40.	3.2	28
105	Diagnostic Test Accuracy of a 2-Transcript Host RNA Signature for Discriminating Bacterial vs Viral Infection in Febrile Children. JAMA - Journal of the American Medical Association, 2016, 316, 835.	7.4	263
106	Comparative Genomics of Carriage and Disease Isolates of <i>Streptococcus pneumoniae</i> Serotype 22F Reveals Lineage-Specific Divergence and Niche Adaptation. Genome Biology and Evolution, 2016, 8, 1243-1251.	2.5	8
107	Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01 _B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. Journal of Infectious Diseases, 2016, 214, 772-781.	4.0	96
108	Density Distribution of Pharyngeal Carriage of Meningococcus in Healthy Young Adults. Pediatric Infectious Disease Journal, 2016, 35, 1080-1085.	2.0	13

#	Article	IF	CITATIONS
109	Low Concentrations of Nitric Oxide Modulate Streptococcus pneumoniae Biofilm Metabolism and Antibiotic Tolerance. Antimicrobial Agents and Chemotherapy, 2016, 60, 2456-2466.	3.2	27
110	Demonstration of the Blood-Stage <i>Plasmodium falciparum</i> Controlled Human Malaria Infection Model to Assess Efficacy of the <i>P. falciparum</i> Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. Journal of Infectious Diseases, 2016, 213, 1743-1751.	4.0	95
111	Development of X-ray micro-focus computed tomography to image and quantify biofilms in central venous catheter models in vitro. Microbiology (United Kingdom), 2016, 162, 1629-1640.	1.8	7
112	Immunological Features and Clinical Benefits of Conjugate Vaccines against Bacteria. Journal of Immunology Research, 2015, 2015, 1-3.	2.2	3
113	Environmental temperature impacts on the performance of QuantiFERON-TB Gold In-Tube assays. Journal of Infection, 2015, 71, 276-280.	3.3	13
114	Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals. Journal of Infectious Diseases, 2015, 211, 1076-1086.	4.0	110
115	Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial. Lancet Infectious Diseases, The, 2015. 15. 172-180.	9.1	9
116	Lack of Evidence for an Unmet Need to Treat Clostridium difficile Infection in Infants Aged <2 Years: Expert Recommendations on How to Address This Issue. Clinical Infectious Diseases, 2015, 60, 912-918.	5.8	24
117	Intracellular residency of Staphylococcus aureus within mast cells in nasal polyps: A novel observation. Journal of Allergy and Clinical Immunology, 2015, 135, 1648-1651.e5.	2.9	39
118	Fluarix quadrivalent vaccine for influenza. Expert Review of Vaccines, 2015, 14, 1055-1063.	4.4	14
119	Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. BMJ, The, 2015, 350, h1554-h1554.	6.0	27
120	Current methods for capsular typing of Streptococcus pneumoniae. Journal of Microbiological Methods, 2015, 113, 41-49.	1.6	70
121	Phase I studies: the role of publicly funded academic-healthcare partnerships. BMJ, The, 2015, 351, h3889.	6.0	0
122	Respiratory tract infection associated with seizures. BMJ, The, 2015, 351, h4659.	6.0	1
123	Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy. Journal of Infection, 2015, 71, 43-52.	3.3	61
124	Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction. Vaccine, 2015, 33, 2015-2021.	3.8	130
125	Paper-based colorimetric enzyme linked immunosorbent assay fabricated by laser induced forward transfer. Biomicrofluidics, 2014, 8, 036502.	2.4	24
126	Administration of AS03B-adjuvanted A(H1N1)pdm09 Vaccine in Children Aged <3 Years Enhances Antibody Response to H3 and B Viruses Following a Single Dose of Trivalent Vaccine One Year Later. Clinical Infectious Diseases, 2014, 58, 181-187.	5.8	9

#	Article	IF	CITATIONS
127	New approaches to the treatment of biofilm-related infections. Journal of Infection, 2014, 69, S47-S52.	3.3	82
128	Extremes of Age Are Associated with Indeterminate QuantiFERON-TB Gold Assay Results. Journal of Clinical Microbiology, 2014, 52, 2694-2697.	3.9	60
129	Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet, The, 2014, 384, 2123-2131.	13.7	247
130	Evidence Base for the Use of Corticosteroids in Septic Shock in Children. Critical Care Medicine, 2014, 42, e83-e84.	0.9	3
131	Ciliated Cultures From Patients With Primary Ciliary Dyskinesia Produce Nitric Oxide in Response to Haemophilus influenzae Infection and Proinflammatory Cytokines. Chest, 2014, 145, 668-669.	0.8	14
132	Pneumococcal Serotype-Specific Antibodies Persist through Early Childhood after Infant Immunization: Follow-Up from a Randomized Controlled Trial. PLoS ONE, 2014, 9, e91413.	2.5	12
133	Pronounced Metabolic Changes in Adaptation to Biofilm Growth by Streptococcus pneumoniae. PLoS ONE, 2014, 9, e107015.	2.5	42
134	Distribution of carried pneumococcal clones in UK children following the introduction of the 7-valent pneumococcal conjugate vaccine: A 3-year cross-sectional population based analysis. Vaccine, 2013, 31, 3187-3190.	3.8	13
135	Picture of the Month—Quiz Case. JAMA Pediatrics, 2013, 167, 483.	6.2	1
136	Nasal self-swabbing for estimating the prevalence of Staphylococcus aureus in the community. Journal of Medical Microbiology, 2013, 62, 437-440.	1.8	39
137	Stroke in paediatric pneumococcal meningitis: a cross-sectional population-based study. Archives of Disease in Childhood, 2013, 98, 647-649.	1.9	18
138	Clostridium difficile in Children: A Review of Existing and Recently Uncovered Evidence. Advances in Experimental Medicine and Biology, 2013, 764, 57-72.	1.6	4
139	Ribosomal Protein SA Haploinsufficiency in Humans with Isolated Congenital Asplenia. Science, 2013, 340, 976-978.	12.6	176
140	Varicella Zoster Virus Central Nervous System Immune Reconstitution Inflammatory Syndrome Presenting in a Child. Pediatric Infectious Disease Journal, 2013, 32, 1283-1284.	2.0	7
141	Phase II Study of a Three-dose Primary Vaccination Course of DTPa-IPV/Hib-MenC-TT Followed by a 12-month Hib-MenC-TT Booster in Healthy Infants. Pediatric Infectious Disease Journal, 2013, 32, 675-681.	2.0	5
142	Clonal Expansion within Pneumococcal Serotype 6C after Use of Seven-Valent Vaccine. PLoS ONE, 2013, 8, e64731.	2.5	21
143	A functional microsatellite of the <i>macrophage migration inhibitory factor</i> gene associated with meningococcal disease. FASEB Journal, 2012, 26, 907-916.	0.5	50
144	Empirical antibiotics for suspected early neonatal sepsis. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2012, 97, F75.1-F75.	2.8	3

#	Article	IF	CITATIONS
145	Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans. Clinical Infectious Diseases, 2012, 55, 19-25.	5.8	224
146	H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study. Clinical Infectious Diseases, 2012, 54, 661-669.	5.8	24
147	Prescribing for children – taste and palatability affect adherence to antibiotics: a review. Archives of Disease in Childhood, 2012, 97, 293-297.	1.9	111
148	Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults. Expert Review of Vaccines, 2012, 11, 889-902.	4.4	18
149	ChAd63-MVA–vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. Molecular Therapy, 2012, 20, 2355-2368.	8.2	196
150	Cephalosporinâ€3′â€diazeniumdiolates: Targeted NOâ€Donor Prodrugs for Dispersing Bacterial Biofilms. Angewandte Chemie - International Edition, 2012, 51, 9057-9060.	13.8	137
151	Managing bone and joint infection in children. Archives of Disease in Childhood, 2012, 97, 545-553.	1.9	83
152	Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children. Vaccine, 2011, 29, 4400-4404.	3.8	69
153	Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. Vaccine, 2011, 29, 7913-7919.	3.8	35
154	13-valent pneumococcal conjugate vaccine (PCV13). Hum Vaccin, 2011, 7, 1012-1018.	2.4	35
155	Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age. Pediatric Infectious Disease Journal, 2010, 29, e80-e90.	2.0	114
156	POLYMORPHISMS IN PARP, IL1B, IL4, IL10, C1INH, DEFB1, AND DEFA4 IN MENINGOCOCCAL DISEASE IN THREE POPULATIONS. Shock, 2010, 34, 17-22.	2.1	13
157	Increase in Serotype 6C Pneumococcal Carriage, United Kingdom. Emerging Infectious Diseases, 2010, 16, 154-155.	4.3	30
158	Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. Expert Review of Vaccines, 2010, 9, 1385-1398.	4.4	33
159	Linezolid an Oral Treatment Option for Staphylococcal Liver Abscess in Chronic Granulomatous Disease. Pediatric Infectious Disease Journal, 2009, 28, 1036-1037.	2.0	1
160	Purpura Fulminans. , 2009, , 45-55.		1
161	Expediting clinical trials in a pandemic. BMJ: British Medical Journal, 2009, 339, b4652-b4652.	2.3	6
162	Opa Protein Repertoires of Disease-Causing and Carried Meningococci. Journal of Clinical Microbiology, 2008, 46, 3033-3041.	3.9	15

#	Article	IF	CITATIONS
163	Acute haematogenous osteomyelitis in children: is there any evidence for how long we should treat?. Current Opinion in Infectious Diseases, 2008, 21, 258-262.	3.1	50
164	Developmental assessment: practice makes perfect. Archives of Disease in Childhood, 2007, 92, 278-278.	1.9	1
165	Emergency management of meningococcal disease: eight years on. Archives of Disease in Childhood, 2007, 92, 283-286.	1.9	56
166	OPSOCLONUS-MYOCLONUS SYNDROME ASSOCIATED WITH GROUP A STREPTOCOCCAL INFECTION. Pediatric Infectious Disease Journal, 2007, 26, 358-359.	2.0	10
167	Platelet and soluble CD40L in meningococcal sepsis. Intensive Care Medicine, 2006, 32, 1432-1437.	8.2	30
168	Sleeping Sickness in Brothers in London. Pediatric Infectious Disease Journal, 2004, 23, 879-881.	2.0	14
169	Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: A retrospective study*. Critical Care Medicine, 2004, 32, 1777-1780.	0.9	76
170	HIV-1 Infection in Children: Current Practice and Future Predictions. Advances in Experimental Medicine and Biology, 2004, 549, 135-148.	1.6	0
171	Clinical expert round table discussion (session 3) at the Margaux Conference on Critical Illness: The role of activated protein C in severe sepsis. Critical Care Medicine, 2001, 29, S75-S77.	0.9	14
172	Coagulation in severe sepsis: A central role for thrombomodulin and activated protein C. Critical Care Medicine, 2001, 29, S62-S67.	0.9	85
173	Dysfunction of Endothelial Protein C Activation in Severe Meningococcal Sepsis. New England Journal of Medicine, 2001, 345, 408-416.	27.0	704
174	Disseminated intravascular coagulation and purpura fulminans secondary to infection. Best Practice and Research in Clinical Haematology, 2000, 13, 179-197.	1.7	32
175	INFECTIOUS PURPURA FULMINANS: CAUTION NEEDED IN THE USE OF PROTEIN C. British Journal of Haematology, 1999, 106, 253-253.	2.5	3